Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL).
In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs. Eluxadoline is being developed for the treatment of IBS-D. As of October 2014, it had reached the Phase III stage of development, and also has been granted a Fast-Track designation by the FDA.
Furiex Pharmaceuticals initially licensed eluxadoline from Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson [J&J]) for the development of the product. Subsequently, Furiex was fully-acquired by Actavis in July 2014 (Furiex Pharmaceuticals, press release, July 2, 2014).
Scope:
In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs. Eluxadoline is being developed for the treatment of IBS-D. As of October 2014, it had reached the Phase III stage of development, and also has been granted a Fast-Track designation by the FDA.
Furiex Pharmaceuticals initially licensed eluxadoline from Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson [J&J]) for the development of the product. Subsequently, Furiex was fully-acquired by Actavis in July 2014 (Furiex Pharmaceuticals, press release, July 2, 2014).
Scope:
- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Eluxadoline including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Eluxadoline for the top 7 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan.
Reasons To Buy:
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for IBS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Eluxadoline performance.
- Obtain sales forecast for Eluxadoline from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, UK and Japan).
Free Sample Request:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Table of Content:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Table of Content:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
No comments:
Post a Comment